Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 9, 2010, Pages 2143-2151

  Fletcher, Olivia ^a,b   Johnson, Nichola ^a   Dos Santos Silva, Isabel ^b   Ashworth, Alan ^a   Nevanlinna, Heli ^c   Heikkinen, Tuomas ^c   Aittomäki, Kristiina ^c   Blomqvist, Carl ^c   Burwinkel, Barbara ^d,e   Bartram, Claus R ^d   Meindl, Alfons ^f   Schmutzler, Rita K ^g   Cox, Angela ^h   Brock, Ian ^h   Elliott, Graeme ^a,b   Reed, Malcolm W R ^h   Southey, Melissa C ⁱ   Smith, Letitia ⁱ   Spurdle, Amanda B ^j   Hopper, John L ⁱ   Couch, Fergus J ^k   Olson, Janet E ^k   Wang, Xianshu ^k   Fredericksen, Zachary ^k   Schürmann, Peter ^l   Waltes, Regina ^l   Bremer, Michael ^l   Dörk, Thilo ^l   Devilee, Peter ^m   Van Asperen, Christie J ^m   Tollenaar, Rob A E M ^m   Seynaeve, Caroline ⁿ   Hall, Per ^o   Czene, Kamila ^o   Humphreys, Keith ^o   Liu, Jianjun ^p   Ahmed, Shahana ^q   Dunning, Alison M ^q   Maranian, Melanie ^q   Pharoah, Paul D P ^q   Chenevix Trench, Georgia ^j,r   Beesley, Jonathan ^j,r   Bogdanova, Natalia V ^l,s   Antonenkova, Natalia N ^s   Zalutsky, Iosif V ^s   Anton Culver, Hoda ^t   Ziogas, Argyrios ^t   Brauch, Hiltrud ^u,v   Ko, Yon Dschun ^w,x   Hamann, Ute ^e   Fasching, Peter A ^y,z   Strick, Reiner ^y   Ekici, Arif B ^y   Beckmann, Matthias W ^y   Giles, Graham G ^aa   Severi, Gianluca ^aa   Baglietto, Laura ^aa   English, Dallas R ⁱ   Milne, Roger L ^ab   Benítez, Javier ^ab,ac   Arias, José Ignacio ^ad   Pita, Guillermo ^ab   Nordestgaard, Børge G ^ae   Bojesen, Stig E ⁱ   Flyger, Henrik ⁱ   Kang, Daehee ^af   Yoo, Keun Young ^af   Noh, Dong Young ^af   Mannermaa, Arto ^ag,ah   Kataja, Vesa ^ah,ai   Kosma, Veli Matti ^ag,ah   García Closas, Montserrat ^aj   Chanock, Stephen ^aj   Lissowska, Jolanta ^ak   Brinton, Louise A ^aj   Chang Claude, Jenny ^e   Wang Gohrke, Shan ^al   Broeks, Annegien ^am   Schmidt, Marjanka K ^am   Van Leeuwen, Flora E ^am   Van't Veer, Laura J ^am   Margolin, Sara ^o   Lindblom, Annika ^o   Humphreys, Manjeet K ^q   Morrison, Jonathan ^q   Platte, Radka ^q   Easton, Douglas F ^q   Peto, Julian ^a,b   more..

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^g UNIVERSITY OF COLOGNE   (Germany)

^h UNIVERSITY OF SHEFFIELD   (United Kingdom)

ⁱ UNIVERSITY OF MELBOURNE   (Australia)

^j QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^k MAYO CLINIC   (United States)

^l HANNOVER MEDICAL SCHOOL   (Germany)

^m LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁿ ERASMUS MEDICAL CENTER   (Netherlands)

^o KAROLINSKA INSTITUTE   (Sweden)

^p GENOME INSTITUTE OF SINGAPORE   (Singapore)

^q UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^r PETER MACCALLUM CANCER CENTRE   (Australia)

^s Research Institute of Oncology and Medical Radiology of the Ministry of Health of the Byelorussian SSR   (Belarus)

^t UNIVERSITY OF CALIFORNIA   (United States)

^u DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^v UNIVERSITY OF TÜBINGEN   (Germany)

^w Johanniter Krankenhaus   (Germany)

^x RUHR UNIVERSITY BOCHUM   (Germany)

^y UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^z UNIVERSITY OF CALIFORNIA   (United States)

^aa CANCER EPIDEMIOLOGY CENTRE   (Australia)

^ab Centro Nacional de Investigaciones Oncológicas   (Spain)

^ac CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^ad Monte Naranco Hospital   (Spain)

^ae GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^af Seoul National University College of Medicine   (South Korea)

^ag UNIVERSITY OF EASTERN FINLAND   (Finland)

^ah KUOPIO UNIVERSITY HOSPITAL   (Finland)

^ai VAASA CENTRAL HOSPITAL   (Finland)

^aj NATIONAL CANCER INSTITUTE   (United States)

^ak INSTITUTE OF ONCOLOGY   (Poland)

^al UNIVERSITY OF ULM MEDICAL SCHOOL   (Germany)

^am NETHERLANDS CANCER INSTITUTE   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN;

ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; MISSENSE MUTATION; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR GENE;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; CELL CYCLE PROTEINS; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MUTATION, MISSENSE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN-SERINE-THREONINE KINASES; RISK FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 77956497347     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-10-0374     Document Type: Article

References (36)

1. Swift M, Reitnauer PJ, Morrell D, Chase CL. Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med 1987;316:1289-94. (Pubitemid 17084026)
2. Thompson D, Duedal S, Kirner J, et al. Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst 2005;97:813-22. (Pubitemid 40909124)
3. Renwick A, Thompson D, Seal S, et al. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet 2006;38:873-5.
4. Bernstein JL, Teraoka S, Southey MC, et al. Population-based estimates of breast cancer risks associated with ATM gene variants c. 7271T>G and c.1066-6T>G (IVS10-6T>G) from the Breast Cancer Family Registry. Hum Mutat 2006;27:1122-8.
5. Gatti RA, Tward A, Concannon P. Cancer risk in ATM heterozygotes: a model of phenotypic and mechanistic differences between missense and truncating mutations. Mol Genet Metab 1999;68:419-23.
6. Khanna KK, Chenevix-Trench G. ATM and genome maintenance: defining its role in breast cancer susceptibility. J Mammary Gland Biol Neoplasia 2004;9:247-62. (Pubitemid 39545742)
7. Ahmed M, Rahman N. ATM and breast cancer susceptibility. Oncogene 2006;25:5906-11.
8. Johnson N, Fletcher O, Palles C, et al. Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility. Hum Mol Genet 2007;16:1051-7.
9. Cox A, Dunning AM, Garcia-Closas M, et al. A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet 2007;39:352-8.
10. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
11. Antoniou AC, Easton DF. Polygenic inheritance of breast cancer: implications for design of association studies. Genet Epidemiol 2003;25:190-202.
12. Fletcher O, Johnson N, Palles C, et al. Inconsistent association between the STK15 F31I genetic polymorphism and breast cancer risk. J Natl Cancer Inst 2006;98:1014-8.
13. Dork T, Bendix R, Bremer M, et al. Spectrum of ATM gene mutations in a hospital-based series of unselected breast cancer patients. Cancer Res 2001;61:7608-15. (Pubitemid 32995055)
14. Spurdle AB, Hopper JL, Chen X, et al. No evidence for association of ataxia-telangiectasia mutated gene T2119C and C3161G amino acid substitution variants with risk of breast cancer. Breast Cancer Res 2002;4:R15.
15. Bretsky P, Haiman CA, Gilad S, et al. The relationship between twenty missense ATM variants and breast cancer risk: the Multiethnic Cohort. Cancer Epidemiol Biomarkers Prev 2003;12:733-8. (Pubitemid 36993163)
16. Stredrick DL, Garcia-Closas M, Pineda MA, et al. The ATM missense mutation p.Ser49Cys (c.146C>G) and the risk of breast cancer. Hum Mutat 2006;27:538-44. (Pubitemid 43865726)
17. Burton PR, Clayton DG, Cardon LR, et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet 2007;39:1329-37.
18. Tavtigian SV, Oefner PJ, Babikyan D, et al. Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer. Am J Hum Genet 2009;85:427-46.
19. Broeks A, Braaf LM, Huseinovic A, et al. The spectrum of ATM missense variants and their contribution to contralateral breast cancer. Breast Cancer Res Treat 2008;107:243-8. (Pubitemid 350265692)
20. Concannon P, Haile RW, Borresen-Dale AL, et al. Variants in the ATM gene associated with a reduced risk of contralateral breast cancer. Cancer Res 2008;68:6486-91.
21. Ng PC, Henikoff S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res 2003;31:3812-4. (Pubitemid 37442253)
22. Easton DF, Pooley KA, Dunning AM, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007;447:1087-93.
23. Hunter DJ, Kraft P, Jacobs KB, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 2007;39:870-4.
24. Stacey SN, Manolescu A, Sulem P, et al. Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet 2007;39:865-9.
25. Stacey SN, Manolescu A, Sulem P, et al. Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet 2008;40:703-6.
26. Zheng W, Long J, Gao YT, et al. Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nat Genet 2009;41:324-8.
27. Thomas G, Jacobs KB, Kraft P, et al. A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet 2009;41:579-84.
28. Frazer KA, Murray SS, Schork NJ, Topol EJ. Human genetic variation and its contribution to complex traits. Nat Rev Genet 2009;10:241-51.
29. Shattuck-Eidens D, Oliphant A, McClure M, et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA 1997;278:1242-50.
30. Seal S, Thompson D, Renwick A, et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 2006;38:1239-41.
31. Rahman N, Seal S, Thompson D, et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 2007;39:165-7.
32. Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer 2009;9:95-107.
33. Gutierrez-Enriquez S, Fernet M, Dork T, et al. Functional consequences of ATM sequence variants for chromosomal radiosensitivity. Genes Chromosomes Cancer 2004;40:109-19. (Pubitemid 38579879)
34. Tavtigian SV, Greenblatt MS, Goldgar DE, Boffetta P. Assessing pathogenicity: overview of results from the IARC Unclassified Genetic Variants Working Group. Hum Mutat 2008;29:1261-4.
35. Tavtigian SV, Greenblatt MS, Lesueur F, Byrnes GB. In silico analysis of missense substitutions using sequence-alignment based methods. Hum Mutat 2008;29:1327-36.
36. Goldgar DE, Easton DF, Byrnes GB, Spurdle AB, Iversen ES, Greenblatt MS. Genetic evidence and integration of various data sources for classifying uncertain variants into a single model. Hum Mutat 2008;29:1265-72.